

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/803146	
	Filing Date	March 17, 2004	
	First Named Inventor	NJ BRITTEN	
	Art Unit	1614	
	Examiner Name	NOT YET ASSIGNED	
Total Number of Pages in This Submission	3	Attorney Docket Number	01559.US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): COMMUNICATION TO EXAMINER
Remarks RECEIVED CENTRAL FAX CENTER OCT 12 2004 		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Pharmacia & Upjohn Company, TIMOTHY J. GUMBLETON REG. 54,143
Signature	<i>Timothy Gumbleton</i>
Date	Oct 11, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	VALERIE L. SCHIPPER
Signature	<i>Valerie L. Schipper</i>
Date	10/12/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT/Docket No. 01559.US1

Serial No. 10/803146

Page 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Examiner : Not Yet Assigned
Applicant(s) : NJ Britten, NA Waldron, JL Watts, JW Hallberg, JW Burns
Serial Number : 10/803146
Filed : 03/17/2004
For : DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT

RECEIVED
CENTRAL FAX CENTER

OCT 12 2004

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION TO EXAMINER

Sir:

Applicants wish to bring to Examiner's attention the applications listed in the table below. They are all assigned to Pfizer or one of its subsidiaries and contain claims or disclosure related to formulations or indications of ceftiofur.

	Serial Number	Title
1.	10/380228	Pharmaceutical Composition Having Modified Carrier
2.	10/704989	Pharmaceutical Composition Having Modified Carrier
3.	10/393098	Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
4.	10/393267	Parenteral Combination Therapy for Infective Conditions
5.	10/706255	Pharmaceutical Composition Having Modified Vehicle
6.	10/687986	Dispersible Pharmaceutical Compositions
7.	10/795191	Dispersible Pharmaceutical Compositions For Treatment of Mastitis and Otic Disorders
8.	10/903662	Dispersible Pharmaceutical Compositions For Treatment of Mastitis and Otic Disorders
9.	10/909050	Dispersible Formulation of An Anti-Inflammatory Agent


FORM PTORSP
Rev. 5/1/03

PATENT/Docket No. 01559.US1

Serial No. 10/803146

Page 2

Respectfully submitted,



Timothy J. Gumbleton, Patent Agent
Registration No. 54,143

Date: Oct 11, 2004

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-2501 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

FORM PTORSP
Rev. 5/1/03